🟢 GSK is trading 4.15% up today on positive lung-cancer trial results

GSK is trading at £1844.00 (+4.15%) after positive lung-cancer trial data strengthened its oncology growth outlook.

• Jideytro delivered a 94% objective response rate in 94 treatment-naïve patients, supporting a planned FDA first-line filing.
• Ris-Rez reduced relapsed small-cell lung-cancer mortality risk by 54% versus topotecan.
• Both datasets were presented at the 2026 World Conference on Lung Cancer; the move was company-specific despite weaker broader-market conditions.